Pres. Biden’s pick to head the FDA, Dr. Robert Califf, previously ran the agency under Obama.
From Natural Products Insider: “There is nothing that I am aware of to suggest that Dr. Califf will be focused on supplements or CBD, in the short term at least,” said Ivan Wasserman, partner at the Amin Talati Wasserman law firm, which represents a number of hemp CBD clients. “He will have his hands full with COVID-19 and supply-chain issues.” “His nomination hearings,” said Wasserman, “may provide more insights on his agenda and views on supplements and other topics.”
“Inspections are down. No progress on NDIs (new dietary ingredients), no progress on enforcing knock-off imports, and no progress on CBD. But that’s what the American public has received,” said Daniel Fabricant, Ph.D., president and CEO of the Natural Products Association (NPA). FDA under Califf worked with state attorneys general to help regulate the supplements industry, purportedly to help the strapped agency keep on top of the market. But Fabricant believes Califf would seek to use FDA’s current authorities to effectively regulate the market for dietary supplements.”
“Not to put words in anyone’s mouth,” said Fabricant, “still, Dr. Califf has a reputation as a sound thinker and I don’t imagine would want to give the American taxpayer lip service when it comes to a regulated commodity that 70% of the country uses daily to maintain their health. Rather, he’ll look for ways to use existing authorities, which are more than adequate as he clearly stated.””
One of them might be to declare CBD as a food ingredient existing before October 1994, the DSHEA cut-off date, like it did in 2018 the hempseed oil which usually contains CBD. Another might be to clarify that CBD is included in the GRN-778 GRAS notice for hempseed oil.